November 8, 2013
The US-based Bristol-Myers Squibb (BMS) has announced its submission of a new drug application (NDA) for the combination therapy of the NS5A inhibitor daclatasvir (DCV) and the NS3 protease inhibitor asunaprevir (ASV) for the treatment of chronic hepatitis C in...read more